These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22971456)

  • 21. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review*.
    Tummon I; Gavrilova-Jordan L; Allemand MC; Session D
    Acta Obstet Gynecol Scand; 2005 Jul; 84(7):611-6. PubMed ID: 15954867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation.
    Tal R; Seifer DB; Shohat-Tal A; Grazi RV; Malter HE
    Fertil Steril; 2013 Aug; 100(2):538-43. PubMed ID: 23684116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-alpha cannot predict its occurrence.
    Loret de Mola JR; Baumgardner GP; Goldfarb JM; Friedlander MA
    Hum Reprod; 1996 Jul; 11(7):1377-80. PubMed ID: 8671470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome.
    Korhonen KV; Savolainen-Peltonen HM; Mikkola TS; Tiitinen AE; Unkila-Kallio LS
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():162-168. PubMed ID: 27865939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome.
    Ohata Y; Harada T; Ito M; Yoshida S; Iwabe T; Terakawa N
    Gynecol Obstet Invest; 2000; 50(3):186-8. PubMed ID: 11014952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation.
    Grynnerup AG; Toftager M; Zedeler A; Bogstad JW; Prætorius L; Grøndahl ML; Yding Andersen C; Sørensen S; Pinborg A; Løssl K
    J Assist Reprod Genet; 2018 Dec; 35(12):2187-2193. PubMed ID: 30232642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic landscape and pathogenic insights: a comprehensive analysis of high ovarian response in infertile women undergoing in vitro fertilization.
    Ruan LL; Lv XY; Hu YL; Chen MX; Jing-Tang ; Zhong ZH; Bao MH; Fu LJ; Luo X; Yu SM; Wan Q; Ding YB
    J Ovarian Res; 2024 May; 17(1):105. PubMed ID: 38760835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follicular fluid renin concentration in patients with polycystic ovaries treated with gonadotrophins in an in vitro fertilisation programme.
    Vrtacnik-Bokal E; Meden-Vrtovec H; Osredkar J; Verdenik I
    Clin Chem Lab Med; 2003 May; 41(5):663-7. PubMed ID: 12812264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
    Palomba S; Falbo A; Carrillo L; Villani MT; Orio F; Russo T; Di Cello A; Cappiello F; Capasso S; Tolino A; Colao A; Mastrantonio P; La Sala GB; Zullo F; Cittadini E;
    Fertil Steril; 2011 Dec; 96(6):1384-1390.e4. PubMed ID: 21982727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian hyperstimulation syndrome and thrombotic events.
    Mor YS; Schenker JG
    Am J Reprod Immunol; 2014 Dec; 72(6):541-8. PubMed ID: 25146913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Outcome of follicular aspiration of selection phase in patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation].
    Zhu WJ; Li XM; Chen XM; Zhang L
    Zhonghua Fu Chan Ke Za Zhi; 2004 Aug; 39(8):522-5. PubMed ID: 15363349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome.
    Abramov Y; Schenker JG; Lewin A; Kafka I; Jaffe H; Barak V
    Fertil Steril; 2001 Jul; 76(1):51-7. PubMed ID: 11438319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study.
    D'Angelo A; Davies R; Salah E; Nix BA; Amso NN
    Fertil Steril; 2004 Feb; 81(2):332-6. PubMed ID: 14967369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients.
    Wu L; Sun Y; Wan J; Luan T; Cheng Q; Tan Y
    Mol Med Rep; 2017 Jul; 16(1):272-280. PubMed ID: 28534980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unsuspected adverse effect of albumin in severe ovarian hyperstimulation syndrome: a case report.
    Darii N; Pavlovic M; Doroftei B; Emil A
    JBRA Assist Reprod; 2019 Oct; 23(4):430-433. PubMed ID: 31058477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.